[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602006020294D1 - Heterozyklische verbindung - Google Patents

Heterozyklische verbindung

Info

Publication number
DE602006020294D1
DE602006020294D1 DE602006020294T DE602006020294T DE602006020294D1 DE 602006020294 D1 DE602006020294 D1 DE 602006020294D1 DE 602006020294 T DE602006020294 T DE 602006020294T DE 602006020294 T DE602006020294 T DE 602006020294T DE 602006020294 D1 DE602006020294 D1 DE 602006020294D1
Authority
DE
Germany
Prior art keywords
heterocyclic
connection
heterocyclic connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020294T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Jun Matsubara
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Tatsuyoshi Tanaka
Shinichi Taira
Tae Fukushima
Haruka Takahashi
Takeshi Kuroda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE602006020294D1 publication Critical patent/DE602006020294D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602006020294T 2005-08-31 2006-08-31 Heterozyklische verbindung Active DE602006020294D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005251055 2005-08-31
PCT/JP2006/317704 WO2007026959A2 (en) 2005-08-31 2006-08-31 Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
DE602006020294D1 true DE602006020294D1 (de) 2011-04-07

Family

ID=37709698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020294T Active DE602006020294D1 (de) 2005-08-31 2006-08-31 Heterozyklische verbindung

Country Status (26)

Country Link
US (3) US8071600B2 (de)
EP (4) EP2287161B1 (de)
JP (1) JP4785677B2 (de)
KR (2) KR101008873B1 (de)
CN (4) CN102702182A (de)
AR (1) AR055203A1 (de)
AT (4) ATE557022T1 (de)
AU (2) AU2006285607B2 (de)
BR (1) BRPI0615140A2 (de)
CA (1) CA2620688C (de)
CY (1) CY1111671T1 (de)
DE (1) DE602006020294D1 (de)
DK (1) DK1919907T5 (de)
ES (4) ES2383948T3 (de)
HK (1) HK1119707A1 (de)
IL (1) IL189383A (de)
MX (1) MX2008002736A (de)
MY (1) MY145670A (de)
PL (1) PL1919907T3 (de)
PT (1) PT1919907E (de)
RU (1) RU2415854C2 (de)
SG (1) SG155180A1 (de)
SI (1) SI1919907T1 (de)
TW (1) TWI329641B (de)
WO (1) WO2007026959A2 (de)
ZA (1) ZA200801888B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258760T3 (es) 2003-07-22 2006-09-01 Arena Pharmaceuticals, Inc. Derivados de diaril y de la urea de arileteroaril usados como moduladores del receptor de la serotonina 5-ht2a utiles para la profilaxis y el tratamiento de desordenes a ellos asociados.
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
CN101479261A (zh) 2006-05-18 2009-07-08 艾尼纳制药公司 3-吡唑基-苯甲酰胺-4-醚、其仲胺及其衍生物作为5-ht2a血清素受体的调节剂用于治疗与其相关的病症
BRPI0712030A2 (pt) 2006-05-18 2012-01-03 Arena Pharm Inc formas cristalinas e processos para preparaÇço de fenil-pirazàis éteis como moduladores dos receptores de serotonina 5-h-t2a
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP1972628A1 (de) * 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizine und aza-analoge Derivate davon als CNS-aktive Verbindungen
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
WO2008154091A1 (en) * 2007-06-08 2008-12-18 National Health Research Institutes Thiourea derivatives
CA2693032A1 (en) * 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
EP2184272A4 (de) * 2007-08-21 2011-11-09 Shionogi & Co Piperazinderivat
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
JP5224616B2 (ja) * 2007-10-29 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環式エーテルまたはチオエーテル誘導体
CA2713378A1 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
US8338406B2 (en) 2008-02-22 2012-12-25 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
MX2010012186A (es) * 2008-05-09 2011-02-22 Univ Emory Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos.
BRPI0916216A2 (pt) * 2008-07-15 2018-03-13 Novartis Ag composto orgânicos
EP2322520A4 (de) * 2008-07-28 2012-04-25 Jiangsu Guohua Invest Co Ltd Aralkylsubstituierte piperidin- oder piperazinderivate und deren verwendung zur behandlung von schizophrenie
MX2011001846A (es) * 2008-09-01 2011-04-04 Neurosearch As Nuevos derivados de piperidina-4-acetamida y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2010062323A2 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
EP2816040B1 (de) * 2008-12-19 2018-10-17 Centrexion Therapeutics Corporation Verfahren zur Herstellung von CCR2-Rezeptorantagonisten und Zwischenprodukte davon
EP3725775A1 (de) * 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridin- und pyrimidincarboxamide als cxcr2-modulatoren
TWI481601B (zh) * 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
BR112012003871A2 (pt) 2009-08-21 2015-09-08 Otsuka Pharma Co Ltd processo para a produção de composto de benzo[b][1,4]diazepina-2,4-diona
EP3091012B1 (de) 2009-12-17 2018-04-11 Centrexion Therapeutics Corporation Ccr2-rezeptorantagonisten und ihre verwendung
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011109679A2 (en) * 2010-03-05 2011-09-09 Amira Pharmaceuticals, Inc. Inhibitors of 5-lipoxygenase
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
JP6486002B2 (ja) 2010-08-23 2019-03-20 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド
CN102206214B (zh) 2011-04-07 2014-03-12 华中科技大学 苯并吡喃酮类衍生物及其应用
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
US9624197B2 (en) * 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9745284B2 (en) * 2013-03-08 2017-08-29 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ether orexin receptor antagonists
EP3495357B1 (de) * 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidine, deren herstellung und verwendung
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CA2989343A1 (en) 2015-06-12 2016-12-15 Yandong Wen Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3397636B1 (de) 2015-12-28 2021-08-04 Honour (R&D) Verfahren zur herstellung von chinolin-2(1h)-on-derivaten
CN112079812B (zh) * 2020-09-29 2021-08-06 浙江大学 哌唑类抗精神病药物关键中间体及其电还原方法
CN112125896B (zh) * 2020-09-29 2021-10-29 湖南省湘中制药有限公司 一种抗精神病药依匹哌唑电化学制备方法
JP2023547892A (ja) * 2020-10-27 2023-11-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５－ｈｔ２ａセロトニン受容体に関連する障害を処置するために有用な５－ｈｔ２ａセロトニン受容体のモジュレーターとしてのピリミジン誘導体
CN115772175A (zh) * 2021-09-07 2023-03-10 中国科学院分子细胞科学卓越创新中心 噻吩并环化合物及其制备方法和应用
IL314361A (en) 2022-01-29 2024-09-01 Suven Life Sciences Ltd Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders
CN115521298A (zh) * 2022-05-09 2022-12-27 江苏慧聚药业股份有限公司 依匹哌唑的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2004670A1 (en) * 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DE69618050T2 (de) * 1995-03-17 2002-07-11 Aventis Pharmaceuticals Inc., Cincinnati Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EP0934932A4 (de) 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
ES2244438T3 (es) 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
AR027134A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
AR027133A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
MXPA03006524A (es) 2001-02-16 2003-09-25 Aventis Pharma Inc Derivados heterociclicos novedosos de amidas y su uso como ligandos para receptor d3 de dopamina.
US6982332B2 (en) 2001-06-07 2006-01-03 Wayne State University Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity
US7342015B2 (en) * 2001-06-29 2008-03-11 H. Lundbeck A/S Indole derivatives
AP2005003250A0 (en) * 2002-09-17 2005-03-31 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
EP1546145A1 (de) 2002-09-26 2005-06-29 Warner-Lambert Company Llc Heterocyclisch substituierte piperazine zur behandlung von schizophrenie
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物

Also Published As

Publication number Publication date
CN102702182A (zh) 2012-10-03
TW200800937A (en) 2008-01-01
IL189383A0 (en) 2008-06-05
CN102558140A (zh) 2012-07-11
TWI329641B (en) 2010-09-01
JP2007091733A (ja) 2007-04-12
ES2382445T3 (es) 2012-06-08
RU2008112224A (ru) 2009-10-10
PT1919907E (pt) 2011-03-23
IL189383A (en) 2013-03-24
EP1919907A2 (de) 2008-05-14
EP2287162A1 (de) 2011-02-23
US8598162B2 (en) 2013-12-03
EP2287162B1 (de) 2012-05-09
ES2383949T3 (es) 2012-06-27
US20090264404A1 (en) 2009-10-22
EP1919907B9 (de) 2012-01-18
AU2010200362A1 (en) 2010-02-18
US20120028920A1 (en) 2012-02-02
PL1919907T3 (pl) 2011-07-29
DK1919907T3 (da) 2011-04-18
CA2620688C (en) 2014-03-25
EP2287161A1 (de) 2011-02-23
ATE549330T1 (de) 2012-03-15
WO2007026959A2 (en) 2007-03-08
SI1919907T1 (sl) 2011-05-31
US20140031334A1 (en) 2014-01-30
CA2620688A1 (en) 2007-03-08
EP2287161B1 (de) 2012-05-09
WO2007026959A3 (en) 2007-08-16
EP2284169B1 (de) 2012-03-14
BRPI0615140A2 (pt) 2010-01-12
EP2284169A1 (de) 2011-02-16
JP4785677B2 (ja) 2011-10-05
RU2415854C2 (ru) 2011-04-10
KR20080033446A (ko) 2008-04-16
KR20100063807A (ko) 2010-06-11
SG155180A1 (en) 2009-09-30
ES2383948T3 (es) 2012-06-27
MX2008002736A (es) 2008-03-26
CY1111671T1 (el) 2015-10-07
MY145670A (en) 2012-03-15
ES2362961T3 (es) 2011-07-15
CN101258147B (zh) 2012-03-21
DK1919907T5 (da) 2011-09-12
ATE499369T1 (de) 2011-03-15
ZA200801888B (en) 2009-07-29
ATE557022T1 (de) 2012-05-15
KR101008873B1 (ko) 2011-01-19
HK1119707A1 (en) 2009-03-13
ES2362961T9 (es) 2012-02-13
CN102850336A (zh) 2013-01-02
US8071600B2 (en) 2011-12-06
CN101258147A (zh) 2008-09-03
AU2006285607A1 (en) 2007-03-08
ATE557021T1 (de) 2012-05-15
EP1919907B1 (de) 2011-02-23
AU2006285607B2 (en) 2010-02-25
AR055203A1 (es) 2007-08-08

Similar Documents

Publication Publication Date Title
DE602006020294D1 (de) Heterozyklische verbindung
DE502006003394D1 (de) Lehnenklappung
DK1937650T3 (da) Heterocykliske forbindelser
DE502006008475D1 (de) Wasserpumpenflügelrad
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DE502006005667D1 (de) Gelenklager
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DE502006006857D1 (de) Wingungserregern
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502006001397D1 (de) Lagerbuchse
ATE485368T1 (de) Hiv - impfung
DE502006003147D1 (de) Verbundgußplatte
DE502006001004D1 (de) Hydrolager
DE502005005839D1 (de) Feldgeerät
ATE541837T1 (de) Oxaphenanthren-derivate
DE502006003210D1 (de) Nohydrogenpolysiloxanen
DE602005003547D1 (de) Fahrradantriebsnabe
DE102006033170A8 (de) Einfassnähmaschine
DE502006002822D1 (de) Ges
DE502006000445D1 (de) Mulchmähdeck
DE102005052834B8 (de) Punktschweißklebverbindung
AT501523A3 (de) Estrich